AKRO
Akero Therapeutics, Inc.
Biotechnology
Market Cap$4.50B
5Y Perf.+115.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AKRO vs ELVN
Revenue, margins, valuation, and 5-year total return — side by side.
ELVN
Enliven Therapeutics, Inc.
Biotechnology
Market Cap$2.45B
5Y Perf.-83.9%
AKRO vs ELVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AKRO | ELVN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $4.50B | $2.45B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-293M | $-104M |
| Total Debt | $36M | $0.00 |
| Cash & Equiv. | $340M | $99M |
AKRO vs ELVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AKRO
ELVN
| Stock | May 20 | Dec 25 | Return |
|---|---|---|---|
| Akero Therapeutics,… (AKRO) | 100 | 215.0 | +115.0% |
| Enliven Therapeutic… (ELVN) | 100 | 16.1 | -83.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AKRO vs ELVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ELVN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Akero Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
AKRO
Akero Therapeutics, Inc.
The Income Pick
AKRO is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.35
- 198.3% 10Y total return vs ELVN's -31.3%
- Lower volatility, beta 0.35, Low D/E 4.9%, current ratio 19.38x
Best for: income & stability and long-term compounding
ELVN
Enliven Therapeutics, Inc.
The Growth Play
ELVN carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 3.2%
- -16.6% revenue growth vs AKRO's -24.6%
- +109.2% vs AKRO's +30.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ELVN | -16.6% revenue growth vs AKRO's -24.6% |
| Quality / Margins | AKRO | 4.0% margin vs ELVN's 3.4% |
| Stability / Safety | AKRO | Beta 0.35 vs ELVN's 1.27 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ELVN | +109.2% vs AKRO's +30.1% |
| Efficiency (ROA) | ELVN | -23.4% ROA vs AKRO's -29.1%, ROIC -32.8% vs -55.3% |
AKRO vs ELVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAKROLAGGINGELVN
ELVNEnliven Therapeutics,…
2leads
AKROAkero Therapeutics, I…
2leads
6 Total Categories
CATEGORYLEADERvs ELVNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AKRO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ELVN6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ELVN3/5
Risk & VolatilityBeta, volatility, and downside exposure
AKRO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AKRO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AKRO and ELVN operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | AKROAkero Therapeutic… | ELVNEnliven Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$318M | -$119M |
| Net IncomeAfter-tax profit | -$293M | -$104M |
| Free Cash FlowCash after capex | -$250M | -$70M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +5.7% | +2.2% |
AKRO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — AKRO and ELVN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | AKROAkero Therapeutic… | ELVNEnliven Therapeut… |
|---|---|---|
| Market CapShares × price | $4.5B | $2.4B |
| Enterprise ValueMkt cap + debt − cash | $4.2B | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -14.57x | -22.51x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 4.89x | 5.08x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — AKRO and ELVN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ELVN leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
ELVN delivers a -24.2% return on equity — every $100 of shareholder capital generates $-24 in annual profit, vs $-31 for AKRO. On the Piotroski fundamental quality scale (0–9), ELVN scores 3/9 vs AKRO's 2/9, reflecting mixed financial health.
| Metric | AKROAkero Therapeutic… | ELVNEnliven Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -30.6% | -24.2% |
| ROA (TTM)Return on assets | -29.1% | -23.4% |
| ROICReturn on invested capital | -55.3% | -32.8% |
| ROCEReturn on capital employed | -42.4% | -31.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.05x | — |
| Net DebtTotal debt minus cash | -$304M | -$99M |
| Cash & Equiv.Liquid assets | $340M | $99M |
| Total DebtShort + long-term debt | $36M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -62.41x | — |
ELVN leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ELVN leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AKRO five years ago would be worth $20,724 today (with dividends reinvested), compared to $14,487 for ELVN. Over the past 12 months, ELVN leads with a +109.2% total return vs AKRO's +30.1%. The 3-year compound annual growth rate (CAGR) favors ELVN at 29.1% vs AKRO's 6.3% — a key indicator of consistent wealth creation.
| Metric | AKROAkero Therapeutic… | ELVNEnliven Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | — | +165.1% |
| 1-Year ReturnPast 12 months | +30.1% | +109.2% |
| 3-Year ReturnCumulative with dividends | +20.1% | +115.3% |
| 5-Year ReturnCumulative with dividends | +107.2% | +44.9% |
| 10-Year ReturnCumulative with dividends | +198.3% | -31.3% |
| CAGR (3Y)Annualised 3-year return | +6.3% | +29.1% |
ELVN leads this category, winning 3 of 5 comparable metrics.
Risk & Volatility
AKRO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AKRO is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than ELVN's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AKRO currently trades 95.3% from its 52-week high vs ELVN's 84.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AKROAkero Therapeutic… | ELVNEnliven Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.35x | 1.27x |
| 52-Week HighHighest price in past year | $57.35 | $48.50 |
| 52-Week LowLowest price in past year | $37.28 | $14.79 |
| % of 52W HighCurrent price vs 52-week peak | +95.3% | +84.9% |
| RSI (14)Momentum oscillator 0–100 | 70.4 | 51.1 |
| Avg Volume (50D)Average daily shares traded | 0 | 1.1M |
AKRO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AKRO as "Buy" and ELVN as "Buy". Consensus price targets imply 5.2% upside for ELVN (target: $43) vs -11.4% for AKRO (target: $48).
| Metric | AKROAkero Therapeutic… | ELVNEnliven Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $48.40 | $43.33 |
| # AnalystsCovering analysts | 14 | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AKRO leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). ELVN leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallAkero Therapeutics, Inc. (AKRO)Leads 2 of 6 categories
Loading custom metrics...
AKRO vs ELVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AKRO or ELVN a better buy right now?
Analysts rate Akero Therapeutics, Inc.
(AKRO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AKRO or ELVN?
Over the past 5 years, Akero Therapeutics, Inc.
(AKRO) delivered a total return of +107. 2%, compared to +44. 9% for Enliven Therapeutics, Inc. (ELVN). Over 10 years, the gap is even starker: AKRO returned +198. 3% versus ELVN's -32. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AKRO or ELVN?
By beta (market sensitivity over 5 years), Akero Therapeutics, Inc.
(AKRO) is the lower-risk stock at 0. 35β versus Enliven Therapeutics, Inc. 's 1. 27β — meaning ELVN is approximately 265% more volatile than AKRO relative to the S&P 500.
04Which is growing faster — AKRO or ELVN?
On earnings-per-share growth, the picture is similar: Enliven Therapeutics, Inc.
grew EPS 3. 2% year-over-year, compared to -29. 8% for Akero Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AKRO or ELVN?
Akero Therapeutics, Inc.
(AKRO) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Enliven Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKRO leads at 0. 0% versus 0. 0% for ELVN. At the gross margin level — before operating expenses — AKRO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AKRO or ELVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AKRO or ELVN better for a retirement portfolio?
For long-horizon retirement investors, Akero Therapeutics, Inc.
(AKRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), +198. 3% 10Y return). Both have compounded well over 10 years (AKRO: +198. 3%, ELVN: -32. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AKRO and ELVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.